Knowledge

Antibody drug conjugates (ADCs) are a rapidly growing field of interest in biopharmaceutics. In comparison to conventional chemotherapy treatments, ADCs have the potential to destroy cancerous cells without damaging healthy cells in the process. In this article we will give you an introduction to this important and rapidly growing field. 

The safe handling of ADCs or other HPAPIs is a complex and elaborate process that requires specialized facilities and a safe, sterile environment. The filling/aliquoting step in particular calls for great care and specific equipment to ensure sterility and rule out any potential cross-contamination as well as potential harm to handling staff.

The manufacturing of bioconjugates is a complex process that involves linking a drug payload with a targeting moiety using a linker. The process is highly specific and requires careful optimization to ensure that the bioconjugate is effective and safe for use in patients. Single-use technology has revolutionized the manufacturing of bioconjugates by offering a range of benefits over traditional stainless-steel manufacturing. Therefore, this article will pay special attention to this subject. 

Bioconjugation is a pharmaceutical technique that is gaining more and more importance, most of all in cancer therapy. In this article, we will provide some basic information on bioconjugation, but also discuss major challenges related to this field.
 

The term "autologous" is most frequently found in the context of cell therapy. In this article, we will therefore take a closer look at this revolutionary therapeutic approach.

What does "allogeneic" mean, precisely? How do allogeneic cell therapies work, and what is the difference to autologous approaches? Questions like these will be answered in this article.

Since the first ADCs entered clinical trials in the 1990s, they have shown great promise in treating a variety of cancers and other diseases. However, the development of ADCs has also been marked by challenges and setbacks, including issues with efficacy, safety, and manufacturing. In this article, we will explore the history of ADCs, from their early development to the latest advances in technology and applications.

Automation is affecting various aspects of our lives, including bioprocessing. In this article, we will explore the advantages that come with this development.

Spray drying often leads to product losses of mAbs or vaccines of more than 30%. Plate-based freezing and thawing solutions enable controlled handling of bulk intermediates safely in a vendor-independent, modular and scalable fluid and cold chain management process. 

The terms "drug substance" and "drug product" are often used synonymously, although there are some fundamental differences between them. We will point them out in the course of this article!

Bioprocessing is a fundamental technology for various aspects of our lives, including the biopharma industry. In this article, we will provide some interesting facts about applications, techniques and future expectations regarding bioprocessing.

The entire biopharma industry depends on intact supply chain in order to provide patients with the drug products they need. However, there are several factors that can put the integrity of supply chain at risk. In this article, we will discuss seven of them and explore what can be done to circumvent them.